Daratumumab (Darzalex) as first-line treatment in combination with bortezomib, melphalan and prednisone if a stem cell transplantation is not an option
In 2019 the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of daratumumab in combination with bortezomib, melphalan and prednisone for the treatment of newly diagnosed multiple myeloma in people who can't have a stem cell transplant.
The manufacturer gave IQWiG one still ongoing study involving 706 participants that provided at least preliminary answers to some questions. One half of the participants were given treatment with the combination bortezomib / melphalan / prednisone, and the other group received this combination plus daratumumab. All of the patients were in relatively good health otherwise.